Medicaid Final Rule Reference Guide

Stay ahead of the curve on the Medicaid Drug Rebate Program’s Final Rule, which takes effect on November 19, 2024, using our comprehensive white paper packed with valuable insights on what provisions could impact different manufacturers and key operational and financial factors to consider! Download it today!

Unlocking Market Access: Insights from Two Labs on Navigating Pharma’s Complex Commercialization Landscape

On the latest episode of ISPE Boston Area Chapter’s The Future of Pharma podcast, Two Labs’ Kyle Felmet and Riparian LLC’s Jennifer Lospinoso join host Samir Gondalia to discuss how pharmaceutical companies can better navigate market access challenges. As the pharmaceutical landscape becomes increasingly intricate, ensuring a successful product launch requires more than innovation; it demands a […]

Navigating Government Pricing for Cell & Gene Therapies

The wave of FDA-approved cell and gene therapies (CGT) is transforming treatment options for diseases that once had few solutions. As more CGTs move from clinical trial to commercial approval and availability, navigating the complexities of government pricing becomes a critical hurdle for emerging manufacturers.

Cell and Gene Therapy Pipeline: Navigating Key Trends and Pricing Dynamics

Cell and gene therapy (CGT) is emerging as one of the most dynamic and innovative fields in the pharmaceutical industry. The journey began in 2017 with the groundbreaking approval of Kymriah (tisagenlecleucel), a CAR-T cell therapy for acute lymphoblastic leukemia. Since then, the pace has only quickened. From 2017 to 2022, seven gene therapies were approved, with another five approvals in 2023 alone. Now, there are over 20 such products on the market, with many more expected by year-end, showcasing the remarkable strides and potential of this sector.